GeNeuro (FRA:GEM) Moat Score: 0/10 (As of Jul. 06, 2026)


FRA:GEM GeNeuro SA FRA:GEM
8 GF Score
Price €0.03
View Full Analysis

What is GeNeuro Moat Score?

GeNeuro has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

GeNeuro has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes GeNeuro might have No Moat - No discernible moat.

GeNeuro  (FRA:GEM) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

GeNeuro Moat Score Related Terms

FRA:GEM
8GF Score
GeNeuro SA FRA:GEM
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GeNeuro Business Description

Address 3 chemin du Pre-Fleur, Plan-les-Ouates, Geneva, CHE, 1228
GeNeuro SA is a clinical-stage biopharmaceutical company focused on understanding and stopping causal factors driving the progression of neurodegenerative and autoimmune diseases. The company's therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W family (W-ENV).
8GF Score

Get the complete analysis for FRA:GEM

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.03
Price